New York, New York–(Newsfile Corp. – January 5, 2025) – WHY: The Rosen Law Firm, a global investment law firm, reminds clients of Dentsply Sirona Inc.'s common stock. (NASDAQ: XRAY) between February 28, 2022 and November 6, 2024, both dates inclusive (the “Class Period”), for the January 27, 2025 is the plaintiff's deadline.
AND THEN: If you purchased Dentsply Sirona common stock during the Class Period you may be entitled to a refund without payment of any out-of-pocket costs or expenses through a possible time payment arrangement.
NEXT TO DO: To join the Dentsply Sirona class action, go to https://rosenlegal.com/submit-form/?case_id=31762 or call Phillip Kim, Esq. at 866-767-3653 or email case@rosenlegal.com for more information. A class action lawsuit has already been filed. If you wish to act as a lead plaintiff, you must move the Court no later than January 27, 2025. The lead plaintiff is the party that represents the other class members in managing the lawsuit.
WHY THE LAW CAME OUT: We encourage investors to select qualified advisors with a track record of success in leadership roles. Often times, the firms issuing the notices do not have the same experience, resources, or any meaningful peer review. Many of these companies don't really need security practices, but are middlemen who refer clients or work with law firms that litigate cases. Be wise in choosing counsel. The Rosen Law Firm represents investors worldwide, focusing its practice on securities class actions and shareholder litigation. The Rosen Law Firm won the largest ever securities settlement for a Chinese company at the time. The Rosen Law Firm was ranked Level 1 by ISS Securities Action (WA:) Services on the number of securities class action settlements in 2017. The firm has been ranked in the top 4 every year since 2013 and has received hundreds of millions of dollars from investors. In 2019 alone the company secured over $438 million from investors. In 2020, founding partner Laurence Rosen was named by Law360 as a Titan of the Spot Bar. Many of the firm's lawyers are accredited by Lawdragon and Top Lawyers.
CREDIT DETAILS: According to the lawsuit, during the Class Action, the defendants made false and / or misleading statements and / or could not present the material necessary to make the statements made, according to the circumstances in which they were made, not lies and deception. In fact, Byte's regulators have been causing serious harm to patients since at least May 2021, as revealed in the back injury reports that Dentsply Sirona filed with the US Food and Drug Administration (“FDA”) in 2024. The problem was that customer service staff and supervising dentists were encouraged to sign up potential patients with other dental issues that would have made them ineligible for Byte treatment. As a result, the defendants' positive statements about Byte's customer experience, and the extended network of dentists responsible for managing each customer's treatment, were misleading and/or unfounded. In addition, Dentsply Sirona has hidden the fact that the high conversion rates are caused by advertising incentives to register patients against each other. When true information enters the market, the lawsuit claims that investors suffer damages.
To join the Dentsply Sirona class action, go to https://rosenlegal.com/submit-form/?case_id=31762 or call Phillip Kim, Esq. call toll free at 866-767-3653 or email case@rosenlegal.com for information about the class action.
No Class is guaranteed. Until the class is confirmed, you are not represented by counsel unless you have retained one. You can choose the advice of your choice. You can remain a member of the missing class and do nothing for now. The investor's ability to share in any future recovery is not dependent on serving as the lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook (NASDAQ:): https://twitter. com/rosen_firm /www.facebook.com/rosenlawfirm/.
Marketing Lawyer. Previous results do not confirm the same result.
——————————-
Contact information:
To view the source of this document, please visit https://www.newsfilecorp.com/release/236082